Patients with severe aortic stenosis ( AS ) who were deemed too high risk or inoperable for conventional aortic valve replacement ( AVR ) in the PARTNER ( Placement of Aortic Transcatheter Valves ) trial were randomized to transcatheter aortic valve replacement ( TAVR ) versus AVR ( PARTNER-A arm ) or standard therapy ( PARTNER-B arm ) .